• Explore /
  • Poster
  • / Nivolumab and ipilimumab for second-line therapy in elderly patients with advanced esophageal squamous cell cancer: Safety interim analysis of the RAMONA trial.

Nivolumab and ipilimumab for second-line therapy in elderly patients with advanced esophageal squamous cell cancer: Safety interim analysis of the RAMONA trial.

Abstract Video & Slides Poster

Authors

null

Nicolai Hartel

Heidelberg University, Mannheim, Germany

Nicolai Hartel , Nadja M Meindl-Beinker , Martin Maenz , Wolfgang Hiegl , Johannes Betge , Ralf Dieter Hofheinz , Arndt Vogel , Stefan Angermeier , Claus Bolling , Maike de Wit , Ralf Jakobs , Meinolf Karthaus , Gertraud Stocker , Peter C. Thuss-Patience , Matthias Philip Ebert

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03416244

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4029)

DOI

10.1200/JCO.2021.39.15_suppl.4029

Abstract #

4029

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Nadja M Meindl-Beinker

First Author: Matthias Philip Ebert

First Author: Hamid Emamekhoo

First Author: Geoffrey Thomas Gibney